Protara Reports Promising Interim Results for TARA-002 in Pediatric Lymphatic Malformations

Protara Therapeutics has shared encouraging interim data from its Phase II STARBORN-1 trial evaluating TARA-002 in children with macrocystic and mixed lymphatic malformations (LMs), a condition with no approved therapies. The study enrolled 12 participants who received at least one dose of TARA-002 via intracystic injection. Eight participants completed the eight-week response assessment, all achieving clinical success. Notably, seven responded after one or two doses, while a child with a 1,739 ml macrocystic lesion required four doses to achieve a complete response. Overall, 83% of patients with macrocystic lesions achieved complete response, and the sole patient with a mixed lesion also reached this endpoint. Two participants completed the 32-week evaluation and remained disease-free. TARA-002 was well tolerated, with mostly mild to moderate adverse events, including fatigue and swelling. No serious safety issues were observed. These results support TARA-002’s potential as a meaningful intervention for pediatric LMs.

25-11-2025